

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**Zynteglo for treating beta-thalassaemia major [ID968]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, see below.

Genetic Alliance UK:

*It should be taken into account that transfusion-dependent beta-thalassaemia mainly affects those from Mediterranean, South Asian, South East Asian and Middle Eastern descent.*

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Would not need to be addressed by the committee (issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal).

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

**Approved by Associate Director (name):** ...Linda Landells.....

**Date:** 31 July 2019